Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy
Journal of Clinical Oncology · 10.03.2025 · 43 (8) · 994-1005
DOI: 10.1200/jco-24-02081 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.03.2025. Verfasst von Shaida Ouladan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the potential of CAR-T cell therapy in CRC by analyzing clinical trials and highlighting prominent CRC-specific targets. We discuss the challenges such as immunosuppressive microenvironment, tumor heterogeneity, and physical barriers that limit CAR-T efficacy. Emerging strategies, such as logic-gated and dual-targeting CAR-T cells, offer practical solutions to overcome these hurdles. Furthermore, we explore the combination of CAR-T cell therapy with immune checkpoint inhibitors to enhance T-cell persistence and tumor infiltration. As the field continues to evolve, CAR-T cell therapies hold significant potential for revolutionizing the treatment landscape of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, McGill University, Montreal, QC, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
ORCID-Profile: Shaida Ouladan, Elias Orouji
Zitieren
APA
Ouladan, S., & Orouji, E. (2025). Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy. Journal of Clinical Oncology, 43(8), 994-1005. https://doi.org/10.1200/jco-24-02081
Vancouver
Ouladan S, Orouji E. Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy. Journal of Clinical Oncology. 2025;43(8):994-1005. doi:10.1200/jco-24-02081
BibTeX
@article{Ouladan2025,
author = {Ouladan, Shaida and Orouji, Elias},
title = {Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {8},
pages = {994--1005},
doi = {10.1200/jco-24-02081}
}
EUVIMED